• The most commonly used thienopyridine is clopidogrel; prasugrel is a new thienopyridine that offers an alternative pharmacological treatment.

  • Use of dual antiplatelet treatment is the standard of care in patients undergoing percutaneous coronary intervention.

  • By inhibiting platelet activation, the thienopyridine antiplatelet agents play a crucial role in the adjunctive treatment of patients with ACS and in patients with a recent myocardial infarction, recent stroke, or established peripheral arterial disease.

Acute coronary syndromes (ACSs) are among the leading causes of death in the developed world and are associated with annual costs of $300 million in the United States alone.1,2  In 2005, approximately 1.5 million patients were discharged from the hospital with a primary or secondary diagnosis of ACS. Overall, morbidity and mortality rates have decreased in patients with ACS, but 25% of patients are still not receiving guideline-recommended care, a...

You do not currently have access to this content.